Nuclear Energy: Worth Getting Paid to Buy It at a More Reasonable Price? (as of 2026-09-01)

As of 2026-09-01. Educational and analytical only. Not investment advice. Company figures come from the companies' own Q2 2026 filings and earnings releases; screen figures come from the levelbox screener's own 2026-09-01 run at 0.20 delta, 30-day target. Where a cash-secured put is mentioned, its max loss and breakeven are stated. Nothing here is an instruction to buy or sell anything.

This article was generated by AI — levelbox's deep-dive tooling — and lightly reviewed. The data is point-in-time and can be wrong. If you spot a mistake, please tell us.

A friend recommends a nuclear stock. The story behind it is one of the better ones on the market right now. If you sell puts, the next question is whether you can get paid to wait for a cheaper entry.

We added a nuclear theme to the screener and ran nineteen names through it on 2026-09-01. Seven of them never reached the ranking.

The demand is real. The reactors arrive in 2028 at the earliest.

Big tech has committed to more than 10 GW of new nuclear capacity. Google signed the first US corporate SMR fleet deal with Kairos Power, targeting 500 MW. AWS is putting $20bn into Pennsylvania alongside Talen's existing nuclear site. GE Vernova's BWRX-300 at Darlington became the first small modular reactor under construction in North America, and TerraPower's Natrium plant in Wyoming has its NRC construction permit.

Here is the timing. No SMR operates in the United States today. First-of-a-kind units are realistically 2028 to 2030, and most planned deployments land in the early-to-mid 2030s.

None of that argues against the sector. It argues about which instrument suits it. A cash-secured put is a two-to-six week commitment that can leave you holding shares. A thesis that pays off in 2032 is indifferent to what happens between now and October.

Seven of nineteen never got ranked

Before scoring anything, the screener applies a floor: peak annual revenue of at least $100m. Anything below that is excluded with its number attached, rather than ranked low.

On 2026-09-01 that removed seven nuclear names:

excluded	peak annual revenue
OKLO	$0m
NANO Nuclear (NNE)	$0m
Lightbridge (LTBR)	$0m
NexGen (NXE)	$0m
Denison (DNN)	$9m
NuScale (SMR)	$37m
Energy Fuels (UUUU)	$78m

That list is most of what people mean when they say "nuclear stocks". The floor is there because a cash-secured put makes you an owner at the strike, and there is no way to judge a fair price for a company with no revenue to value.

Those names still carry the fattest premiums in the sector. The premium is fat because the valuation question is open, which is a different transaction from being paid to wait at a price you have already decided you like. Both are real trades. They pay you for different things.

What was left, and where BWXT landed

Twelve names cleared the gate. The run below is at 0.20 delta, 30-day target:

rank	name	segment	score	quality	growth	value	health
1	GEV	reactor OEM	0.56	0.63	0.33	1.00	1.00
2	URA	ETF	0.41	0.00	0.00	1.00	0.00
3	NUKZ	ETF	0.40	0.00	0.00	1.00	0.00
4	UEC	fuel	0.38	0.10	0.50	0.50	0.33
5	CEG	IPP	0.37	0.10	0.00	0.67	0.67
6	J	services	0.36	0.27	0.33	0.67	0.67
7	NLR	ETF	0.34	0.00	0.00	1.00	0.00
8	CCJ	fuel	0.34	0.20	0.33	0.67	0.33
9	BWXT	reactor OEM	0.34	0.37	0.00	0.67	0.33
10	TLN	IPP	0.30	0.37	n/a	n/a	0.00
11	VST	IPP	0.30	0.10	0.33	1.00	0.00
12	LEU	fuel	0.28	0.10	0.00	0.33	0.33

The three ETFs get scored on premium, liquidity and entry alone, so their 0.00 growth and health readings are a scoring convention and say nothing about the funds.

BWXT sits ninth of twelve. Mid-table, not disqualified.

BWXT: a good business, an awkward price

The operating figures deserve the attention they get. Q2 2026 revenue was $901.6m, up 18% year-on-year. Backlog hit $8.40bn, up 40%, on a trailing twelve-month book-to-bill of 1.7x. Management raised full-year guidance to $662–672m of adjusted EBITDA and $345–360m of free cash flow. In July it agreed to sell the medical business to Nordic Capital for up to $800m while keeping a minority stake, and closed the Precision Components Group acquisition. It builds the reactors for the US naval propulsion programme, which is about as durable a franchise as this sector offers.

The screener's own re-rating check agrees, and labels BWXT's revenue trend accelerating on 18.0% year-on-year growth. It attaches two qualifiers to that label: valuation context rich, and margins compressing.

Those qualifiers are what the score is picking up.

The multiple has run ahead of the growth. P/E of 41.96 against 14.1% earnings growth, PEG 1.67. The GARP lens scores that combination 0.00, the only zero among the non-ETF names except CEG and LEU.

Cash conversion is thinner than the headline suggests. Free-cash-flow margin of 4.1% and debt-to-equity of 1.51. GE Vernova converts at 38.0% with debt-to-equity of 0.28. Both companies grow. They turn revenue into cash very differently.

The trend has not turned. BWXT trades 16.3% below its 200-day moving average and its support line slopes down. The health lens runs three checks and BWXT passed one, the re-rating check. Both price checks failed.

At $161.54 the stock sits 33% under its 52-week high of $241.82. The nearest support the model finds is $147.74, which is also the 52-week low, so nothing is established above it.

Get paid to wait, or just wait?

Selling a put means naming a price and collecting income while you wait there. It works once you can answer two questions. Would you be content owning this at the strike, and does the premium pay you enough for the wait?

On BWXT the first answer is arguable in a good way. A naval-reactor franchise raising backlog 40% is a reasonable thing to want to own at the right number.

The second is harder. On the 2026-09-01 close the 150-strike put expiring 2026-09-18 marked around $1.60 a share, about $160 for one contract at roughly 0.19 delta, with a modelled assignment probability of 18.6%. Max loss about $14,840 if the shares go to zero, breakeven near $148.40.

That breakeven sits just under the 52-week low, which sounds like room until you notice support is still sliding and the multiple is still rich. You collect about 1.1% of the capital you tie up for seventeen days.

BWXT has a mechanical problem too. It lists no weekly expiries and six expirations in total, and the quoted spread on that strike was wide. Turning positions over every few weeks needs a dense expiry ladder. Monthly-only names limit the cadence whatever you make of the business.

What the run suggests

The sector divides into what you can underwrite and what you cannot, and the screener draws that line for you at $100m of revenue. Fuel, enrichment, the reactor builders and the independent power producers have revenue and valuations you can argue with. The SMR developers have order books and optionality, and they did not make the list.

Among the twelve that did, the purest expression of the theme and the best-scoring stock were different names. GE Vernova topped the run at 0.56 while selling gas and wind equipment alongside its reactors, so it waters the theme down. BWXT gives you the concentrated version at 0.34. Choosing between those is a judgement about what you are buying, and no screen makes it for you.

A strong business can also be an awkward entry, which is why valuation and trend get scored beside quality. "Get paid to wait for your price" needs you to pick the price first. On this data, $150 is not obviously it.

The nuclear theme is live in the levelbox screener if you want to run it against your own delta and DTE settings. These numbers move. This is a snapshot of 2026-09-01.